|
|
|
ALPN Description — Alpine Immune Sciences Inc
Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to autoimmune and inflammatory diseases. Co.'s ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor, and a proliferation inducing ligand, cytokines, which play the roles in the activation, development, and survival of B cells. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and CD28 antagonist used for the treatment of autoimmune and inflammatory diseases. In immuno-oncology, Co.'s ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor used for the treatment of cancer.
Company Name: |
Alpine Immune Sciences Inc |
Website: |
www.alpineimmunesciences.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding ALPN: |
31 |
Total Market Value Held by ETFs: |
$411,596,749.12 |
Total Market Capitalization: |
$4,235,000,000 |
% of Market Cap. Held by ETFs: |
9.72% |
|
ETF |
ALPN Weight |
ALPN Amount |
XBI |
1.77% |
$117,698,745 |
VTI |
0.01% |
$101,669,456 |
IWM |
0.10% |
$57,853,345 |
VXF |
0.04% |
$43,750,597 |
LABU |
1.10% |
$11,843,918 |
IWO |
0.10% |
$11,147,228 |
IWN |
0.09% |
$10,741,542 |
DWAS |
1.19% |
$10,662,330 |
VTWO |
0.10% |
$9,284,909 |
VHT |
0.04% |
$7,081,708 |
List of all 31 ETFs holding ALPN
» |
|
|
|
|
Hold (2.25 out of 4)
0th percentile
|
|
|